MUTIERTE IMMUNGLOBULINBINDENDE POLYPEPTIDE

European patent · EP3221338 · In force

Register entry

Publication number
EP3221338
Application number
EP15797942
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 16, 2015
Published
Sep 27, 2017
Granted
Oct 28, 2020
Protection ends at the latest
Nov 15, 2035
Next annual fee due
Nov 30, 2026
IPC classes
C07K 14/31 (2006.01)
B01D 15/38 (2006.01)
C12N 15/09 (2006.01)
Priority
SE 1451376 17.11.2014
GB 201510261 12.06.2015
GB 201510263 12.06.2015
PCT application
PCT/EP2015/076642 16.11.2015
PCT publication
WO2016/079034 26.05.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 1, 2025

    Change

    Published in Swissreg on 01.12.2025

  2. Dec 1, 2024

    Change

    Published in Swissreg on 01.12.2024

  3. Dec 1, 2023

    Change

    Published in Swissreg on 01.12.2023

  4. May 9, 2023

    Address changed

    Representative
    Valipat S.A., c/o BOVARD SA Neuchâtel, Rue des Noyers 11, 2000 Neuchâtel → VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 09.05.2023

  5. Dec 1, 2022

    Change

    Published in Swissreg on 01.12.2022

  6. Nov 4, 2020

    Agent entered

    Representative
    Valipat S.A., c/o BOVARD SA Neuchâtel, Rue des Noyers 11, 2000 Neuchâtel

    Published in Swissreg on 04.11.2020

  7. Oct 28, 2020

    Granted

    Published in Swissreg on 28.10.2020

Parties

Holder

Cytiva BioProcess R&D AB

Björkgatan 30, 751 84 Uppsala, SE

Agent

VALIPAT

c/o BOVARD LTD Optingenstrasse 16, 3013 Bern

Inventor

ANDER, Mats

751 84 Uppsala, SE

BJORKMAN, Tomas

751 84 Uppsala, SE

RODRIGO, Gustav

751 84 Uppsala, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.